Croatian hematologists also recommend aspirin to 90.3%, 67.7%, 61.3%, and 48.4% of MF patients with cardiovascular risk factors, prior thrombosis, JAK2-mutated MF, and post-PV MF, respectively. This evidence concerns the gene JAK2 and acquired polycythemia vera.